Eli Lilly has launched Tanstrive (selpercatinib) in India for patients with advanced or metastatic cancers driven by alterations in the RET gene. Selpercatinib is a targeted therapy that works to block abnormal…
HARMONi-6 Demonstrates Significant Overall Survival Benefits Among NSCLC Patients
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide. In the Phase III HARMONi-6 study, ivonescimab has achieved significant and clinically meaningful improvement in overall survival as a…
Jazz Pharmaceuticals Drug Fails in Phase 3 Lung Cancer Test
Jazz Pharmaceuticals has updated that its lung cancer drug, Zepzelca, failed to meet the goal of improving overall survival in a late-stage study. The company has shared the trial results with U.S….
Blood-Based Risk Score Could Predict Lung Cancer Risk Early
Currently, lung cancer screening programs are targeted primarily towards older individuals with a history of smoking. Undoubtedly, smoking is the leading risk factors but at the same time it is also true…
Simple Urine Test Could Identify Lung Cancer at Early Stage
Most lung cancer cases are identified at advanced stages and thus, complicate the treatment and reduce survival chances. Early identification of lung cancer is helpful in saving more lives as the disease…
Merck-Kelun Lung Cancer Drug Outperforms Keytruda in Trial
According to Phase 3 study results, Merck-Kelun combo can reduce the risk of tumor progression by 65% in patients with lung cancer. The study has been conducted in China and is the…
India’s First 7-Minute NSCLC Shot Launched Costing ₹3.7 Lakh Per Dose
India has taken a major step towards lung cancer treatment with launch of a new seven-minute NSCLC injection. Roche Pharma India has introduced a new drug called Tecentriq and is designed to…
Study Finds that Many NSCLC Patients Never Receive Treatment
According to a new study, an alarming number of patients with advanced lung cancer are not receiving treatment, despite many advances over recent decades. These new findings are from a large population-based…